Zynerba Pharma (ZYNE) Misses Q4 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2015 Financial Results and Operational Highlights
March 14, 2016 7:00 AM EDTPositive Initial Phase 1 ZYN002 Single Rising Dose Results Reported; Phase 1 Multiple Rising Dose Trial Underway
FDA Grants ZYN002 Orphan-Drug Designation for Fragile X Syndrome
Three ZYN002 Phase 2a Trials Planned for Initiation in Second Half 2016
DEVON, Pa., March 14, 2016 (GLOBE NEWSWIRE) --... More
